Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01133951 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Helicobacter Pylori Eradication to Prevent Gastric Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of May 2020 to Jan 2012
    • Study completion date: May 2020 to May 2032
    v9
  2. 2 versions Re-verified since Jun 10, 2012, no change to tracked fieldsv7-v8
  3. Enrollment target: 3158 to 3000v6
  4. Lead sponsor: Second Military Medical University to Jie-Jun Wang
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 3000 to confirmed 3158
    • Site details revised
    v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Study Status, Referencesv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection appears to reduce the risk of gastric cancer. However, several recent controlled interventional trials by H. pylori eradication to prevent gastric cancer have yielded disappointing results. The exact effect of H.pylori eradication on prevention of gastric cancer is unclear up to now. To clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether H pylori eradication would reduce the incidence of gastric cancer in a high-risk population in China.
Trial Details
NCT Number NCT01133951
Lead Sponsor Jie-Jun Wang
Conditions
(from sponsor)		 Helicobacter Infections, Stomach Neoplasms
Related terms Helicobacter Infections, Precancerous Conditions, Stomach Neoplasms
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov